Nabriva Therapeutics (NASDAQ:NBRV) Hits New 52-Week Low at $3.28

Nabriva Therapeutics plc (NASDAQ:NBRVGet Rating)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $3.28 and last traded at $3.28, with a volume of 35825 shares changing hands. The stock had previously closed at $3.82.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on shares of Nabriva Therapeutics in a research note on Monday. They set a “hold” rating on the stock.

Nabriva Therapeutics Trading Down 6.3 %

The company has a debt-to-equity ratio of 0.01, a current ratio of 2.81 and a quick ratio of 2.01. The company has a fifty day moving average of $6.31 and a 200-day moving average of $6.99. The firm has a market capitalization of $75.06 million, a PE ratio of -0.13 and a beta of 1.46.

Nabriva Therapeutics (NASDAQ:NBRVGet Rating) last posted its earnings results on Wednesday, August 3rd. The biotechnology company reported ($4.50) earnings per share for the quarter, beating the consensus estimate of ($5.00) by $0.50. Nabriva Therapeutics had a negative return on equity of 95.18% and a negative net margin of 131.91%. The company had revenue of $9.19 million for the quarter, compared to analyst estimates of $8.53 million. On average, sell-side analysts anticipate that Nabriva Therapeutics plc will post -17 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nabriva Therapeutics

Several institutional investors have recently bought and sold shares of NBRV. Frazier Life Sciences Management L.P. bought a new position in Nabriva Therapeutics during the first quarter valued at about $179,000. Renaissance Technologies LLC grew its position in shares of Nabriva Therapeutics by 102.1% in the second quarter. Renaissance Technologies LLC now owns 795,938 shares of the biotechnology company’s stock valued at $145,000 after purchasing an additional 402,144 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in shares of Nabriva Therapeutics in the fourth quarter valued at about $214,000. 0.53% of the stock is currently owned by institutional investors.

About Nabriva Therapeutics

(Get Rating)

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia.

Read More

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.